Required Line For Here. Required Line For Here.Required Line For Here. Required Line For Here. Required Line For Here. Required Line For Here.

Company Profile

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE527.156.3 (+1.21 % )
PREV CLOSE (Rs.) 520.85
OPEN PRICE (Rs.) 521.40
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 34431
TODAY'S LOW / HIGH (Rs.)521.40 537.50
52 WK LOW / HIGH (Rs.)517.6 711.55
NSE527.15 6.5 (+1.25 % )
PREV CLOSE(Rs.) 520.65
OPEN PRICE (Rs.) 522.00
BID PRICE (QTY) 527.15 (15 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 798533
TODAY'S LOW / HIGH(Rs.) 520.20 537.85
52 WK LOW / HIGH (Rs.)518.2 711.9

Company News

Date Heading Details
30-May-2019 Glenmark Pharma reports 7% rise in Q4 consolidated net profit <p align="justify">Glenmark Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2019.</p><p align="justify">The company has reported a rise of 26.99% in its net profit at Rs 281.29 crore for the quarter under review as compared to Rs 221.51 crore for the same quarter in the previous year. Total income of the company increased by 17.82% at Rs 1,755.67 crore for Q4FY19 as compared Rs 1,490.12 crore for the corresponding quarter previous year.</p><p align="justify">On the consolidated basis, the company has reported a rise of 6.61% in its net profit at Rs 161.66 crore for the quarter under review as compared to Rs 151.63 crore for the same quarter in the previous year. Total income of the company increased by 10.78% at Rs 2,602.53 crore for Q4FY19 as compared Rs 2,349.37 crore for the corresponding quarter previous year.</p><p align="justify">For the year ended March 31, 2019, the company has reported a rise of 59.92% in its net profit at Rs 1,622.11 crore as compared to Rs 1,014.35 crore for the previous year. Total income of the company increased by 18.45% at Rs 6,780.48 crore for year under review as compared to Rs 5,724.20 crore for year ended March 31, 2018.</p><p align="justify">For the year ended March 31, 2019, on the consolidated basis, the company has reported a rise of 15.07% in its net profit at Rs 925.00 crore as compared to Rs 803.87 crore for the previous year. Total income of the company increased by 9.56% at Rs 10,073.61 crore for year under review as compared to Rs 9,194.47 crore for year ended March 31, 2018.</p>
30-May-2019 Glenmark to raise funds up to $200 million <p align="justify">Glenmark Pharmaceuticals has received an approval for raising of funds up to $200 million by issue of non-convertible debentures (in form of bonds or otherwise) or bonds, whether denominated in Indian Rupee and/or foreign currency(ies), though a public issue or a private placement in accordance with the provisions of the applicable law. Proceeds from these debt securities issuance will be used mainly to refinance existing debt. The Board of Directors of the company at its meeting held on May 29, 2019, approved the same. <br></p><p align="justify">Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).<br></p>
30-May-2019 Glenmark Pharma surges on reporting 7% rise in Q4 consolidated net profit <p align="justify">Glenmark Pharmaceuticals is currently trading at Rs. 552.80, up by 5.45 points or 1.00% from its previous closing of Rs. 547.35 on the BSE.<br></p><p align="justify">The scrip opened at Rs. 533.00 and has touched a high and low of Rs. 555.60 and Rs. 533.00 respectively. So far 26675 shares were traded on the counter.<br></p><p align="justify">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.<br></p><p align="justify">Last one week high and low of the scrip stood at Rs. 575.00 and Rs. 533.00 respectively. The current market cap of the company is Rs. 15589.79 crore.<br></p><p align="justify">The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.55% and 13.90% respectively.</p><p align="justify">The company has reported a rise of 26.99% in its net profit at Rs 281.29 crore for the quarter ended March 31, 2019 as compared to Rs 221.51 crore for the same quarter in the previous year. Total income of the company increased by 17.82% at Rs 1,755.67 crore for Q4FY19 as compared Rs 1,490.12 crore for the corresponding quarter previous year.</p><p align="justify">On the consolidated basis, the company has reported a rise of 6.61% in its net profit at Rs 161.66 crore for the quarter under review as compared to Rs 151.63 crore for the same quarter in the previous year. Total income of the company increased by 10.78% at Rs 2,602.53 crore for Q4FY19 as compared Rs 2,349.37 crore for the corresponding quarter previous year.</p><p align="justify">For the year ended March 31, 2019, the company has reported a rise of 59.92% in its net profit at Rs 1,622.11 crore as compared to Rs 1,014.35 crore for the previous year. Total income of the company increased by 18.45% at Rs 6,780.48 crore for year under review as compared to Rs 5,724.20 crore for year ended March 31, 2018.</p><p align="justify">For the year ended March 31, 2019, on the consolidated basis, the company has reported a rise of 15.07% in its net profit at Rs 925.00 crore as compared to Rs 803.87 crore for the previous year. Total income of the company increased by 9.56% at Rs 10,073.61 crore for year under review as compared to Rs 9,194.47 crore for year ended March 31, 2018.<br></p>
30-May-2019 Board recommends Dividend Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 29, 2019, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2018-19 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
27-May-2019 Glenmark gets final USFDA's nod for Aspirin and Extended-Release Dipyridamole Capsules <p align="justify">Glenmark Pharmaceuticals' subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food &amp; Drug Administration (USFDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.<br></p><p align="justify">According to IQVIA sales data for the 12 month period ending March 2019, the Aggrenox Capsules, 25 mg/200 mg market achieved annual sales of approximately $165.6 million.<br></p><p align="justify">Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).<br></p>
27-May-2019 Glenmark Pharmaceuticals to raise funds through issue of debt securities <p align="justify">Glenmark Pharmaceuticals is planning to raise funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency (ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt. <br></p><p align="justify">The meeting of the Board of Directors of the company is scheduled to be held on May 29, 2019, to consider the same.</p><p align="justify">Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).<br></p>
27-May-2019 Glenmark gains on getting USFDA's nod for Aspirin and Extended-Release Dipyridamole Capsules <p align="justify">Glenmark Pharmaceuticals is currently trading at Rs. 564.20, up by 5.15 points or 0.92% from its previous closing of Rs. 559.05 on the BSE.<br></p><p align="justify">The scrip opened at Rs. 562.00 and has touched a high and low of Rs. 564.25 and Rs. 557.70 respectively. So far 1516 shares were traded on the counter.<br></p><p align="justify">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.<br></p><p align="justify">Last one week high and low of the scrip stood at Rs. 594.90 and Rs. 555.20 respectively. The current market cap of the company is Rs. 15774.61 crore.<br></p><p align="justify">The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.55% and 13.90% respectively.<br></p><p align="justify">Glenmark Pharmaceuticals' subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food &amp; Drug Administration (USFDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.</p><p align="justify">According to IQVIA sales data for the 12 month period ending March 2019, the Aggrenox Capsules, 25 mg/200 mg market achieved annual sales of approximately $165.6 million.</p><p align="justify">Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).<br></p>
27-May-2019 Glenmark Pharmaceuticals informs about media release <p>Glenmark Pharmaceuticals has informed about submission of media release which is self explanatory.&nbsp; <p>The above information is a part of company's filings submitted to BSE.</p>
27-May-2019 Announcement under Regulation 30 (LODR)-Press Release / Media Release Glenmark Pharmaceuticals receives ANDA approval for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg
27-May-2019 Update on board meeting The Board Meeting to be held on 29/05/2019 has been revised to 29/05/2019 This is to inform you that the meeting of the Board of Directors of the Company scheduled on Wednesday, 29 May, 2019, will consider, apart from audited financial result and declaration of dividend, also consider the proposal to enable raising of funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency(ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt. Please treat this as the intimation required under Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The above is for your information.

Enquiry For

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested